Defendant
5 cases as defendant.
Company overview. Neurent Medical Ltd. (Irish parent) and its wholly owned US subsidiary Neurent Medical Inc. — commonly "Neurent Medical" — is a private, venture-backed medical device company headquartered in Oranmore, Co. Galway, Ireland, with US operations in Braintree, Massachusetts. Founded in the mid-2010s (2014–2015 per sources) by Brian Shields and David Townley as a spinout from the BioInnovate Ireland programme at NUI Galway, it remains founder-led and private. Tracxn lists roughly 31 employees (July 2024); the company has raised about $99M total, including a €62.5M ($74M) Series C announced in February 2026, from investors including Atlantic Bridge, Life Sciences Partners, and Fountain Healthcare Partners. Revenue figures are not publicly disclosed.
Products / operations. Neurent develops and sells the NEUROMARK® System, a minimally invasive, impedance-controlled radiofrequency (RF) ablation device indicated for use in ENT surgery to disrupt posterior nasal nerves in patients with chronic rhinitis. The system comprises a single-use, handheld bipolar RF device and a reusable console; it received FDA 510(k) clearance in 2021, with a next-generation version cleared in June 2025. The company is pursuing broader chronic inflammatory sinonasal indications.
Patent-litigation posture. Neurent is an operating company, not an NPE. Its six tracked cases split evenly (3 plaintiff, 3 defendant), reflecting an active two-way dispute with competitor Aerin Medical rather than one-sided assertion. Neurent is defendant in Aerin Medical Inc. et al. v. Neurent Medical Inc. et al. (D. Del., filed July 2023), where Aerin and The Foundry, LLC assert eight patents against NEUROMARK; it is plaintiff in Neurent Medical Ltd. v. Aerin Medical Inc. (D. Del., filed September 2024), asserting four of its own patents against Aerin's RhinAer®. The Delaware actions were consolidated (1:23-cv-00756-JLH). Neurent has also appeared as petitioner in PTAB IPRs challenging Aerin/Foundry patents, with Aerin filing counter-IPRs against Neurent's patents. Venue is the District of Delaware, not a plaintiff-friendly forum like E.D. Tex.
Notable context. The dispute pits two commercial rivals in RF ablation for chronic rhinitis; The Foundry is a medtech incubator whose patents Aerin reportedly exclusively licenses. PTAB final written decisions issued in 2025 (e.g., IPR2024-00282 finding all challenged claims unpatentable), and Aerin appealed to the Federal Circuit (Aerin v. Neurent, No. 25-2100, filed September 2025), which is pending.
Aerin appeals the PTAB's Final Written Decision in IPR2024-00282 invalidating all challenged claims of the '286 patent. The appeal is pending and consolidated with 25-2099 and 25-2100; no docket entries after October 23, 2025 were available.
Federal Circuit appeal by Aerin Medical Inc. from the PTAB Final Written Decision in IPR2024-00277, which held claims of U.S. Patent 11,241,271 unpatentable. The appeal was docketed as 25-2099 and remains pending.
Aerin and The Foundry asserted eight patents, including the '077 patent, against Neurent's NEUROMARK nasal-airway treatment device. The case was stayed after PTAB instituted IPR2024-00669 and was consolidated with related matters; counterclaims and motions to dismiss were pending.
Aerin and Foundry sued Neurent in Delaware alleging infringement of eight patents, including the '286 patent, by Neurent's NEUROMARK System. The case was stayed pending IPR final written decisions; after the PTAB invalidated the '286 claims and Aerin appealed, the current docket posture was unconfirmed.
The Foundry, LLC appealed PTAB decisions in IPR2024-00279, IPR2024-00280, and IPR2024-00669. The Federal Circuit dismissed the consolidated appeals by order dated August 27, 2026, under Fed. R. App. P. 42(b).